DALLAS, March 30, 2010 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring Oxygen Biotherapeutics Inc. (Nasdaq:OXBT). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
It is available at: http://www.beaconequity.com/i/OXBT
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Oxygen Biotherapeutics Inc. (OXBT), formerly Synthetic Blood International Inc., is engaged in the business of developing biotechnology products with a focus on oxygen delivery to tissue. The Company is developing Oxycyte, an oxygen carrier for use in surgical and similar medical situations. OXBT has developed a family of perfluorocarbon-based oxygen carriers for use in personal care, topical wound healing and other topical indications.
Message Board Search for OXBT: http://www.boardcentral.com/boards/OXBT
In the report, the analyst notes:
"During the three months ended January 31, 2010, the Company incurred approximately $185,000 in costs to develop and commercialize the Dermacyte topical cosmetic. Included in this amount are costs related to gel formulation, testing and packaging design.
"OXBT recently announced that the company has begun distribution for its newly formulated Dermacyte(TM) Oxygen Concentrate for the beauty and skin care market. The over-the-counter product is a scientifically designed perfluorocarbon concentrate to enhance oxygen delivery to skin. Dermacyte(TM) Oxygen Concentrate is the first product in a broad and diverse cosmetic line currently under development."
To read the entire report visit: http://www.beaconequity.com/i/OXBT
See what investors are saying about OXBT at penny stock forum
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.